NASDAQ:AVROAvrobio Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Avrobio Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $17.77 -0.06 (-0.34 %) (As of 07/3/2020 04:00 PM ET) Add Compare Share Today's Range$17.30Now: $17.77▼$18.0350-Day Range$15.09MA: $19.73▼$22.9652-Week Range$9.76Now: $17.77▼$29.32Volume246,468 shsAverage Volume404,294 shsMarket Capitalization$640.25 millionP/E RatioN/ADividend YieldN/ABeta1.73 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media AVROBIO, Inc., a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease. The company's lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical trial for the treatment of Fabry disease. It is also developing AVR-RD-02 that has completed pre-clinical trials for the treatment of type 1 Gaucher disease; AVR-RD-03, which is in preclinical development to treat Pompe disease; and AVR-RD-04 that has completed pre-clinical studies for treating cystinosis. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingAvrobio has received a consensus rating of Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $33.60, Avrobio has a potential upside of 89.1% from its current price of $17.77.Amount of Analyst CoverageAvrobio has only been the subject of 2 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesAvrobio has received 140 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAvrobio has received 109 “underperform” votes. (Add your “underperform” vote.)Community SentimentAvrobio has received 56.22% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Avrobio and other stocks. Vote “Outperform” if you believe AVRO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AVRO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAvrobio does not currently pay a dividend.Dividend GrowthAvrobio does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avrobio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.78% of the stock of Avrobio is held by insiders.Percentage Held by Institutions82.27% of the stock of Avrobio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Avrobio are expected to decrease in the coming year, from ($3.15) to ($3.21) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avrobio is -6.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avrobio is -6.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvrobio has a P/B Ratio of 3.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.45 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AVRO Previous Symbol CUSIPN/A CIKN/A Webwww.avrobio.com Phone617-914-8420Debt Debt-to-Equity RatioN/A Current Ratio20.77 Quick Ratio20.77Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.87 per share Price / Book3.03Profitability EPS (Most Recent Fiscal Year)($2.66) Net Income$-72,960,000.00 Net MarginsN/A Return on Equity-44.12% Return on Assets-41.47%Miscellaneous Employees49 Outstanding Shares36,030,000Market Cap$640.25 million Next Earnings Date8/13/2020 (Estimated) OptionableNot Optionable NASDAQ:AVRO Rates by TradingView Receive AVRO News and Ratings via Email Sign-up to receive the latest news and ratings for AVRO and its competitors with MarketBeat's FREE daily newsletter. Avrobio (NASDAQ:AVRO) Frequently Asked Questions How has Avrobio's stock been impacted by COVID-19 (Coronavirus)? Avrobio's stock was trading at $18.02 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AVRO stock has decreased by 1.4% and is now trading at $17.77. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Avrobio? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avrobio in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Avrobio. When is Avrobio's next earnings date? Avrobio is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Avrobio. How were Avrobio's earnings last quarter? Avrobio Inc (NASDAQ:AVRO) posted its quarterly earnings results on Thursday, May, 7th. The company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.66) by $0.11. View Avrobio's earnings history. What price target have analysts set for AVRO? 7 Wall Street analysts have issued 12-month price objectives for Avrobio's shares. Their forecasts range from $13.00 to $43.00. On average, they expect Avrobio's share price to reach $33.60 in the next year. This suggests a possible upside of 89.1% from the stock's current price. View analysts' price targets for Avrobio. Has Avrobio been receiving favorable news coverage? News headlines about AVRO stock have been trending negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Avrobio earned a news sentiment score of -2.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the stock's share price in the next several days. View the latest news about Avrobio. Are investors shorting Avrobio? Avrobio saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 1,960,000 shares, an increase of 13.3% from the June 15th total of 1,730,000 shares. Based on an average trading volume of 341,000 shares, the days-to-cover ratio is currently 5.7 days. Currently, 6.7% of the company's stock are sold short. View Avrobio's Current Options Chain. Who are some of Avrobio's key competitors? Some companies that are related to Avrobio include Twist Bioscience (TWST), Alector (ALEC), Bill.com (RVMD), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), Adverum Biotechnologies (ADVM), Beam Therapeutics (BEAM), I-Mab (BDTX), Sorrento Therapeutics (SRNE), Regenxbio (RGNX), Mesoblast (MESO), Sangamo Therapeutics (SGMO), Cortexyme (CRTX), NanoString Technologies (NSTG) and Coherus Biosciences (CHRS). View all competitors. What other stocks do shareholders of Avrobio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avrobio investors own include Crispr Therapeutics (CRSP), Agile Therapeutics (AGRX), Amarin (AMRN), Axsome Therapeutics (AXSM), Biohaven Pharmaceutical (BHVN), Gilead Sciences (GILD), ImmunoGen (IMGN), Nabriva Therapeutics (NBRV), Selecta Biosciences (SELB) and Zynerba Pharmaceuticals (ZYNE). Who are Avrobio's key executives? Avrobio's management team includes the following people: Mr. Geoff MacKay, Co- Founder, Pres, CEO & Director (Age 53)Mr. Steven N. Avruch, VP, Gen. Counsel & Sec. (Age 58)Mr. Jeffrey Medin Ph.D., Scientific FounderMr. Erik Ostrowski, CFO & Treasurer (Age 46)Dr. Kim Warren, Head of Operations When did Avrobio IPO? (AVRO) raised $75 million in an IPO on Thursday, June 21st 2018. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities served as the underwriters for the IPO and Wedbush Securities was co-manager. What is Avrobio's stock symbol? Avrobio trades on the NASDAQ under the ticker symbol "AVRO." How do I buy shares of Avrobio? Shares of AVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Avrobio's stock price today? One share of AVRO stock can currently be purchased for approximately $17.77. How big of a company is Avrobio? Avrobio has a market capitalization of $640.25 million. The company earns $-72,960,000.00 in net income (profit) each year or ($2.66) on an earnings per share basis. Avrobio employs 49 workers across the globe. What is Avrobio's official website? The official website for Avrobio is www.avrobio.com. How can I contact Avrobio? Avrobio's mailing address is ONE KENDALL SQUARE BUILDING 300 SUITE 201, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-914-8420 or via email at [email protected] This page was last updated on 7/5/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
